Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
R&D Licensing
Filter     Order     Display # 
Date Item Title Hits
12 Mar 2010 ˙Ipsen Grants Rhythm Exclusive Worldwide License 28
11 Mar 2010 AstraZeneca Extends Branded Generics Capability With Torrent Agreement 6
11 Mar 2010 Medivir outlicenses MIV-210 to Daewoong Pharmaceutical Co. Ltd. for clinical development 4
10 Mar 2010 TRANSGENE SIGNS AN EXCLUSIVE OPTION AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALISATION OF ITS IMMUNOTHERAPY PRODUCT TG4010 5
09 Mar 2010 Omeros Licenses PDE7 Compounds for Parkinson's Disease Program 7
08 Mar 2010 Acetylon Licenses Powerful Discovery Methodology and Platform from Harvard University and the Dana-Farber Cancer Institute for Development of Further Next-Generation Class II-Selective HDAC Inhibitor Compounds 56
03 Mar 2010 NicOx and Bausch + Lomb Announce Worldwide Licensing Agreement for NCX 116 9
03 Mar 2010 Transition Therapeutics Announces Licensing and Collaboration Agreement With Lilly 8
03 Mar 2010 Bristol-Myers Squibb and Allergan Enter Global Agreement on Investigational Neuropathic Pain Medicine 148
02 Mar 2010 SHIONOGI ENTERS INTO EXCLUSIVE LICENSE AGREEMENT WITH QUATRX PHARMACEUTICALS TO MARKET OSPEMIFENE 7
25 Feb 2010 Adamis Pharmaceuticals Signs Agreement to Acquire Prostate Cancer Drug Candidates 60
25 Feb 2010 Regulus Therapeutics and GlaxoSmithKline Establish New Collaboration to Develop and Commercialize microRNA Therapeutics Targeting miR-122 93
24 Feb 2010 Entered into Global Partnership with Basilea for an Azole Antifungual Agent Isavuconazole 118
18 Feb 2010 Biogen Idec and Swedish Orphan Biovitrum Update Hemophilia Partnership Agreement 60
16 Feb 2010 AstraZeneca and Rigel Pharmaceuticals Sign Worldwide License Agreement for Late-Stage Development Product -- Fostamatinib Disodium (R788) -- for the Treatment of Rheumatoid Arthritis (RA) 69
15 Feb 2010 Meda in-licenses exclusive rights to Xerese 90
09 Feb 2010 Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitis C therapy 14
08 Feb 2010 Sunesis Grants Carmot Therapeutics License to Its Drug Discovery Technology 145
08 Feb 2010 Teva Acquires Marketing Rights for Oral Laquinimod in the Nordic and Baltic Regions 121
08 Feb 2010 Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche 140
08 Feb 2010 3SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 122
04 Feb 2010 Cannasat Announces Signing of Letter of Intent for In-Licensing of Parkinson's Disease Technology 45
04 Feb 2010 Lung Rx LLC, A Subsidiary Of United Therapeutics Corporation, And mondoBIOTECH holding AG Announce Today a Global Strategic Partnership Agreement for the Development Of Aviptadil Platform 29
04 Feb 2010 TenX Biopharma Licenses Zanolimumab From Genmab 16
03 Feb 2010 APEIRON AND GSK SIGN AN EXCLUSIVE LICENSE AGREEMENT FOR APEIRON'S THERAPEUTIC ENZYME PROJECT APN01 181
02 Feb 2010 Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for Cancer 40
02 Feb 2010 Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trial 19
01 Feb 2010 Starpharma and Lilly Sign New Drug Delivery Collaboration for Human Pharmaceuticals 225
28 Jan 2010 Pacgen Signs Research Collaboration Agreements 39
28 Jan 2010 Patrys to work with CSL to explore antibody drugs 86
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 30 of 1094

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Biologic and Immune Therapy of S. aureus Infections

Order Now

Recommended Report

RNA Therapeutics
Order Now

Subscribe La Merie Biologics